EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Overview of Alcohol Use Disorder

Henry R Kranzler

American Journal of Psychiatry · 01.08.2023 · 180 (8) · 565-572

DOI: 10.1176/appi.ajp.20230488 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Psychiatry, erschienen am 01.08.2023. Verfasst von Henry R Kranzler. Beteiligte Einrichtung: Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, and Mental Illness Research, Education, and Clinical Center, Vetera…. Hauptthemen laut MEDLINE: Alcoholism, Alcohol Deterrents. Die Arbeit wurde bisher 110-mal zitiert (Crossref) und nennt 72 Literaturangaben. Gefördert von: NIAAA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alcohol is regularly consumed throughout most of the world, including by nearly half the U.S. population age 12 or older. Heavy drinking, which is also common, contributes to multiple adverse medical, psychiatric, and social outcomes and more than 140,000 deaths annually in the United States. It is the major risk factor for alcohol use disorder (AUD), whose current U.S. prevalence is 11%. However, AUD is undertreated, with less than 15% of individuals with a lifetime diagnosis receiving any treatment. Risk of AUD is nearly equally genetic and environmental. AUD is responsive to psychosocial treatments, including cognitive-behavioral therapy and motivational enhancement therapy. Alcohol affects multiple neurotransmitter systems, and thus pharmacotherapy for AUD is also effective. The three medications approved in the United States to treat AUD-disulfiram, naltrexone (oral and long-acting injectable formulations), and acamprosate-are underprescribed, despite being considered first-line treatments in clinical practice guidelines. Two medications not approved for treating AUD, topiramate and gabapentin, have shown efficacy in treating the disorder and are used off-label. Recent studies of novel drug candidates, including psychedelics and phosphodiesterase-4 inhibitors, are promising additions for the treatment of AUD, although they require further evaluation before being used clinically. Despite the growing availability of efficacious psychosocial and pharmacological treatments for AUD, it remains a highly stigmatized condition. Research aimed at enhancing the identification and treatment of AUD, including precision therapeutics, could broaden the acceptability of AUD treatment, benefiting affected individuals and their families and reducing the stigma associated with the disorder.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlcoholismAlcohol DeterrentsHumansUnited StatesChildAcamprosateDisulfiramNaltrexoneEthanol

Stichwörter der Autor:innen

AlcoholPsychopharmacologySubstance-Related and Addictive Disorders

Substanzen

Alcohol DeterrentsAcamprosateDisulfiramNaltrexoneEthanol

Autor:innen und Institutionen

  • Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, and Mental Illness Research, Education, and Clinical Center, Veterans Integrated Service Network 4, Crescenz Veterans Affairs Medical Cen…

Förderung

  • NIAAA NIH HHS

Zitieren

APA

Kranzler, H. R. (2023). Overview of Alcohol Use Disorder. American Journal of Psychiatry, 180(8), 565-572. https://doi.org/10.1176/appi.ajp.20230488

Vancouver

Kranzler HR. Overview of Alcohol Use Disorder. American Journal of Psychiatry. 2023;180(8):565-572. doi:10.1176/appi.ajp.20230488

BibTeX
@article{Kranzler2023,
  author = {Kranzler, Henry R},
  title = {Overview of Alcohol Use Disorder},
  journal = {American Journal of Psychiatry},
  year = {2023},
  volume = {180},
  number = {8},
  pages = {565--572},
  doi = {10.1176/appi.ajp.20230488}
}
Kostenlos starten →